Royalty Report: Drugs, Cancer, Disease – Collection: 321858


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pharmaceuticals
  • Antibody
  • Biotechnology
  • Assay
  • Diagnostic
  • DNA
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 321858

License Grant
This amendment increases the royalties for dostarlimab and adds terms for Zejula.
License Property
Dostarlimab is an anti-PD-1 antagonist antibody.

Zejula TM is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.

Field of Use
Dostarlimab is under development for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors.

Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

IPSCIO Record ID: 348663

License Grant
By the Amendment, both parties agree to permit Licensee to conduct development and commercialization of Zejula.  

In addition, under the Amendment, Licensor granted increased royalties upon sales of JEMPERLI (dostarlimab).

Additionally, Licensee has agreed to certain diligence commitments with respect to the future development of JEMPERLI, and the parties have agreed to review such commitments under regular joint review committee meetings going forward.

License Property
Zejula is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, which has received U.S. approval.  

JEMPERLI (dostarlimab) is an anti-PD-1 antagonist antibody.

Field of Use
Zejula is for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.

JEMPERLI (dostarlimab) is under development for multiple oncological disorders.

IPSCIO Record ID: 266704

License Grant
Licensor grants to Licensee a royalty bearing license in the Territory in the Field, with the right to grant sublicenses, under the Compound Patent Rights, which Compound Patent Rights license shall be exclusive and the Licensor Know-How, which Licensor Know-How license shall be non-exclusive, to Develop, Manufacture, have Manufactured, use, import, export and Commercialize the Licensed Compounds and the Licensed Products in the Field in the Territory during the Term.
License Property
The patents include Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose) polymerase(P ARP) inhibitors;  Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors;  Pharmaceutically acceptable salts of 2-{ 4-[(3S)-piperidin-3-yl]phenyl} -2-indazole-7-carboxamide; and, Pyridazinone derivatives as PARP inhibitors.

Licensed Compounds shall mean those certain Licensor compounds currently known as M_-4827 with the following chemical name 2 [4 (3S) 3 PIPERIDINYLPHENYL] 2H INDAZOLE 7 CARBOXAMIDE and M_-2512 with the following chemical name 6 (3 [(4 CYCLOPENTYL 3 OXYPIPERAZIN 1 XL)CARBONYL] 4 FLUOROBENZYL] 4,5 DIMETHYLPYRIDAZIN 3(21-l) ONE], and with respect to both, shall include any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof that but for the license granted, would infringe the Compound Patent Rights.

M_-4827, also known as Niraparib, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor in cancer patients as a monotherapy.

M_-2512 is the backup PARP inhibitor compound.

Field of Use
This agreement includes the development of niraparib for the treatment of tumor.  Niraparib is aprescribed PARP inhibitor to treat cancer.

IPSCIO Record ID: 325366

License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLC”).

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

IPSCIO Record ID: 386935

License Grant
The parties collaborated to create and develop bispecific antibodies using Licensor’s DuoBody technology platform.

Under this original agreement, Licensee had the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations.

Licensee received approval from the FDA for amivantamab, as RYBREVANT, a therapy that was created using Danish Licensor’s proprietary DuoBody bispecific technology platform.

License Property
Amivantamab has been approved in the United States and the European Union under the name RYBREVANT for the treatment of certain adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with epidermal growth factor receptor (“EGFR”) exon 20 insertion mutations. The two antibody libraries used to produce amivantamab were both generated by Licensor. The antibody pair used to create amivantamab was selected in collaboration between the parties.
Field of Use
The rights grants is used for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab, created using Licensor’s DuoBody technology platform is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets.

IPSCIO Record ID: 192822

License Grant
The Licensee entered into a settlement and license agreement with the Licensor resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as Keytruda. The Licensee will pay royalties on the worldwide sales of Keytruda for a non-exclusive license to market Keytruda in any market in which it is approved.
License Property
anti-PD-1 antibody drug, nivolumab, produceScomplete or partial responses in non-small-cell lung cancer, melanoma, and renal-cell cancer, in a clinical trial with a total of 296 patients.
Field of Use
This agreement pertains to the pharmaceutical industry.  Anti-PD-1 antibody for the treatment of cancer, such as Keytruda.

IPSCIO Record ID: 369278

License Grant
Licensor hereby grants to Licensee a royalty-bearing, non-transferable license, with the right to grant sublicenses as provided in Agreement, under the Licensor Technology and Licensor Trademarks, which license shall be non-exclusive with respect to the Merck Know-How and exclusive (even as to Licensor, except to the extent necessary for Licensor to perform its obligations under this Agreement with respect to any Licensor Technology (other than the Merck Know-How) and the Licensor Trademarks, to Exploit the Compounds and Products in the Licensee Field in the Licensee Territory.  The foregoing license grant by Licensor does not include any grant of rights under the Licensor Technology or Licensor Trademarks to Exploit any active pharmaceutical compound that is not a Compound, other than, to the extent applicable, any API(s) Controlled by Licensor (if any) that are included in a Product that is deemed to be a Single Agent Product pursuant to this Agreement.
License Property
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), containing a Compound alone or in combination with other APIs.  For the sake of clarity, all forms, presentations, doses and formulations of a pharmaceutical product containing a Compound shall be considered the same Product for purposes of this Agreement, so long as each form, presentation, dose and formulation contains the same Compound and same other APIs (and no other Compounds or other APIs).

Compound means (a) the Initial Compound; (b) the compound licensed to Licensor under the Merck License Agreement and known as MK-2512; or (c) with respect to both (a) and (b), any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof.

Licensor Patents means all Patents Controlled by Licensor during the Term that are necessary or useful to Exploit the Compounds or Products in the Licensee Field in the Licensee Territory.  Licensor Patents include, as of the Effective Date, those Patents set forth in Exhibit 1.117, the Merck Patents and AstraZeneca Patents.    
US #8071623 – Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US #8436185 – Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US #8188084 – Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP)

Trademark means any word, name, symbol, colour, designation, slogan, catch phrase or device or any combination thereof used or intended to be used in commerce and indicating the source for a product or service, including any domain name, trademark, trade dress, brand mark, trade name, brand name, logo or business symbol, any registrations of any of the foregoing or any pending applications therefor.

Field of Use
The collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer. Niraparib is an oral, once daily, potent, and highly selective PARP inhibitor that is currently being evaluated in Phase 3 clinical trials for ovarian and breast cancer.

IPSCIO Record ID: 311804

License Grant
Irish Licensee has a license with Licensor for the development and U.S. commercialization of Zepzelca.
License Property
Zepzelcaâ„¢ (lurbinectedin), a product approved by FDA in June 2020 and recently launched in the U.S. for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy.

Licensor is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. An integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer.

Field of Use
The Field of Use is for the treatment of lung cancer in adult patients specifically SCLC (small cell lung cancer).

Licensee is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases – often with limited or no options.

IPSCIO Record ID: 118015

License Grant
The Company received an exclusive, worldwide license to patent rights and related know-how covering the PARP diagnostic assay from Licensor, a not-for-profit institution.
License Property
The patent covers the PARP diagnostic assay.  PARP is Poly (ADP Ribose) Polymerase.   Also known as Adenosine Diphosphate Ribosyl Transferase or ADPRT.

Polymerase ('PARP'), also known as Adenosine Diphosphate Ribosyl Transferase or ADPRT, functions in connection with radiation and chemotherapy on cancerous cells.

Field of Use
The Company believes that its knowledge of DNA repair activity may be applied to monitor or screen individuals for susceptibility to cancer, immune deficiencies and chemotherapeutic drug resistance.  The Company believes that a simple and inexpensive serum-based test may give a reliable surrogate indication of the level of PARP in white blood cells.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 367327

License Grant
In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property
Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.

U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors

Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

Field of Use
Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

IPSCIO Record ID: 27631

License Grant
The Licensee has the exclusive right to develop, manufacture and commercialize Opdivo in all territories worldwide except Japan, South Korea and Taiwan (where the Licensor was responsible for all development and commercialization prior to the amendment). The alliance agreement was amended to provide for additional collaboration activities in Japan, South Korea and Taiwan pertaining to Opdivo and several other Licensee compounds including ipilimumab, lirilumab, urelumab and BMS-986016 (anti-LAG3). Both parties have the right and obligation to jointly develop and commercialize the compounds. The Licensee is responsible for supply of the product.
License Property
The agreement is to develop and commercialize Opdivo, an anti-PD-1 human monoclonal antibody being investigated as an anti-cancer treatment. Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells. It is being investigated as an anticancer treatment. It is in Phase III trials (which commenced in 2012) in non-small cell lung cancer, renal cell cancer and melanoma.
Field of Use
The parties jointly own a patent covering Opdivo as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension). In December 2014, the FDA approved Opdivo for unresectable (inoperable) or metastatic melanoma, and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo was also approved in Japan in July 2014 for the same indication. The FDA has granted Fast Track designation for Opdivo in three tumor types non-small cell lung cancer, renal cell carcinoma and metastatic melanoma, and it is in the registrational process for melanoma and non-small cell lung cancer in the U.S. and Europe. The FDA granted Breakthrough Therapy designation for Hodgkin Lymphoma in 2014.

IPSCIO Record ID: 28485

License Grant
The Licensee entered into an exclusive, worldwide License Agreement with a University for the AC Technology.
License Property
The AC Technology is based on the concept of haptenization.  

Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine.  By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.

Field of Use
The Licensee is a development stage biotechnology company specializing primarily in the development and future commercialization of individualized cancer vaccines.  Our proposed vaccines consist of autologous (the patient's own) cancer cells that have been treated with a chemical ('haptenized') to make them more visible to the patient's immune system.  Our previous clinical trials for the AC Vaccine have concentrated on melanoma and ovarian carcinoma, which are our primary indications, and non-small cell lung cancer.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 371878

License Grant
Licensor in-licensed to Licensee the exclusive worldwide rights to any and all preventative, therapeutic and/or diagnostic uses related to cancer in humans and viral infections in humans (including, but not limited to, coronaviruses) for stenoparib. Pursuant to the license agreement, Licensor are solely responsible for the development of stenoparib during the term of the agreement.
License Property
Licensee has amended its license agreement with Licensor  to expand it’s field-of-use to include anti-viral uses of Stenoparib (formerly E7449).

Stenoparib, a novel inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase (PARP), and IXEMPRA® (ixabepilone), a selective microtubule inhibitor, which also has, in clinically relevant doses, a unique inhibitory action against Tankyrases, another important group of DNA damage repair enzymes. DNA damage repair mechanisms are crucial to mammalian cell survival and replication, and so inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancer. Tankyrases are enzymes involved in the stabilization and maintenance of telomeres (the ends of chromosomal DNA) during cell replication, and so disruption of Tankyrases is thought to provide an additional mechanism of impeding cancer cell growth.

Field of Use
Field of use is for treatment for cancer in humans and viral infections in humans.

Stenoparib is currently being evaluated for the treatment of advanced ovarian cancer in a DRP®-guided Phase 2 clinical trial.

The expansion of the field-of-use rights will support Allarity in its advancement of Stenoparib as a potential anti-viral therapy for COVID-19.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.